Navigation Links
Sosei Announces Successful Completion of AD 923 Pharmacokinetic,Study in the USA

TOKYO, May 22, 2007 /PRNewswire-FirstCall/ -- Sosei Group Corporation , a biopharmaceutical company, today announces the successful completion of a study of its fentanyl sublingual spray (AD 923), an opioid analgesic for the treatment of cancer breakthrough pain.

This was a pharmacokinetic Phase I single centre, open-label, single dose, cross-over, randomised study of AD 923 versus Actiq(R) (oral transmucosal fentanyl citrate lozenge) and versus fentanyl citrate injection. The study was conducted in healthy human volunteers, under an IND in the United States. All of the primary and secondary objectives of the study were achieved.

The more rapid absorption of fentanyl from AD 923 compared with Actiq(R) was statistically significant, with substantial plasma exposure seen within 10 minutes. The median Tmax (time to maximum plasma concentration) for AD 923 was 40 minutes compared with 120 minutes for Actiq(R). In addition, the higher absolute bioavailability of AD 923 compared with Actiq(R) was also statistically significant. Both formulations were well tolerated with no significant safety issues identified.

Sosei has reached agreement with EU regulatory authorities to move AD 923 directly into Phase III trials and plan to file a CTA (clinical trial application) in the second half of 2007. Following the outcome of this pharmacokinetic study the company will continue its discussions with the FDA regarding the detailed requirements for the Phase III programme in the USA.

Mr Shinichi Tamura, President & CEO of Sosei, said: "These data demonstrate that AD 923 has the potential to provide significantly faster onset of analgesia compared with existing therapy. Additionally, the higher absolute bioavailability indicates more predictable pain relief across the patient population. These factors together with the ease of administration will provide an optimised product with a rapid onset of ac
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

Post Your Comments:
(Date:11/6/2009)...e-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin B...ta-based, biopharmaceutical company developing hum...munodeficiency Virus) and other infectious agents,...results and provided an operational update. ,, ...ve Officer commented, "We are pleased with our pro...
(Date:11/6/2009)...e-FirstCall/ -- Caraco Pharmaceutical Laboratories...romethamine ophthalmic solution, 0.5% following a ...ation (FDA) for Sun Pharma,s Abbreviated New Drug ...mic solution on the first day following patent exp...ally equivalent to Acular® Ophthalmic Solutio...
(Date:11/6/2009)...ewswire/ -- , - Trial Will Compare NXL103...nt of Multi-Resistant Staphylococcus Aureus (MRSA)...aceutical company focused on the discovery and,dev... the significant global,problem of microbial resis...,antibacterial NXL103 (flopristin/linopristin), ha...
Breaking Medicine Technology:GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4New Complimentary Wallet Card to Tackle Concussions Head On 58903 1New Complimentary Wallet Card to Tackle Concussions Head On 58903 2CTIA West Wireless Health Institute Qualcomm and CommNexus San Diego Present 3A San Diego The Nations Hub for Wireless Healthcare 58900 1CTIA West Wireless Health Institute Qualcomm and CommNexus San Diego Present 3A San Diego The Nations Hub for Wireless Healthcare 58900 2Verenium Announces Proposed Public Offering of Common Stock 14359 1Verenium Announces Proposed Public Offering of Common Stock 14359 2Verenium Announces Proposed Public Offering of Common Stock 14359 3
...t of TRILOGY ACS clinical trial to study Prasug...atients, TOKYO and INDIANAPOLIS, June 23 Daiichi... and Company (NYSE: LLY ),said that the U.S. Food...view period for the prasugrel new drug application...during the review period. This three,month extensi...
...n who would like to have,children but who have not...their lives, the door to a new option has opened w... technique known as,vitrification, a quick freezin.... In what researchers are calling the most exhaust...ed that children born after the freezing,procedure...
Other Medicine Technology:FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel 2FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel 3FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel 4New Research Just Released: Women Can Now Safely Postpone Motherhood Until Time Is Right 2
(Date:11/9/2009)... young athletes are under increasing pressure to p...a University Health System study of 519 junior ten...reases the risk of injury. Researchers who analyze...n junior competition found that players who specia...from tournaments for medical reasons, typically in...
(Date:11/8/2009)...Newswire-USNewswire/ -- Jon O,Brien, president of ...nt about the passage of HR 3962: ,, "Behavior ... lot about core values. We in the prochoice commun...rcome the struggles ordinary Americans have making...afford basic healthcare or have to choose between ...
(Date:11/8/2009)...ition promotes self-assurance, research finds , ...mother may have been right when she told you to si...ture could make you feel more confident about your...ing up straight gives a good impression to other p...a psychology professor at Ohio State University, s...
(Date:11/8/2009)...Newswire-USNewswire/ -- Speaker Nancy Pelosi and D...g the House passage of H.R. 3962, the Affordable H...vote of 220 to 215. Below are the Speaker,s openi...st received a call from the President of the Unite...at victory for the American people. I thank the Pr...
(Date:11/8/2009)...eeze-drying of biopharmaceuticals to be available ...ty. , Toronto, ON (PRWEB...d CEO of Therapure Biopharma Inc. today announced ...l scale pharmaceutical grade freeze dryer and expe...lization) available for contract manufacturing of ...
Breaking Medicine News(10 mins):Health News:Young tennis players who play only 1 sport are more prone to injuries 2Health News:Catholics for Choice Statement on Healthcare Reform Bill 2Health News:Good Posture May Inspire Confidence 2Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2
...o receive a vaccine to protect them against severe... are less likely to contract a serious disease, ac...rvard Medical School studied more than 740 childre... -- a bacterium that causes a person to become res...
...snapshot of the nation's health, put together by t...ws that nearly a third of Americans are obese //an...rth continues to rise, reaching a new record high ...om 1990. The life expectancy for boys born in 2001...
...with men and cars? Why doesn't he notice how much ...ep a grip on the remote control? And the most bewi...me? The answers, says social philosopher Michae...the technology to prove it. "What Could He Be T...
...and its symptoms have been shown to accelerate dea...ooked at the elderly in particular. // A new s...g in the community and not in assisted-living faci...e presence of depression and then did so again at ...
...e tells us high heeled shoes are not good for the ...that assumption. British researchers find no relat...opment of knee osteoarthritis.// About 2 perce... has led investigators to speculate a lifetime of ...
...a popular herbal supplement thought to have anti-c...sical and mental abilities, and help people cope w...rly used by pregnant women, particularly in Asian ...f pregnant women were taking herbal supplements, i...
Other Medicine News:Health News:Diabetes, obesity rates shooting up 2Health News:How a man's mind really works 2
Shandon Pathcentre Netmon Service
Shandon Excelsior Tissue Processor
Shandon Gross-Star Grossing Workbench
Shandon Hyperclean 20 Fume Handling Station
Medicine Products: